JPX and head and neck squamous cell carcinoma: Collectively, our results demonstrated that JPX can competitively bind miR-193-3p, leading to less PLAU inhibition mediated by miR-193-3p, providing new insights into exploring potential molecular and regulatory mechanisms of JPX in HNSCC.